Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339036 · ClinicalTrials.gov registry record · Phase 2
CapTemY90 for Grade 2/3 NET Liver Metastases
A Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT04339036 is a Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2 that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 70 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04339036, a Phase 2 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.
Conditions Studied
Interventions
- DRUG Capecitabine Oral Product
- DRUG Temozolomide Oral Product
- COMBINATION_PRODUCT transarterial radioembolization
Study Locations (4)
California
- UC San Diego - La Jolla
Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04339036
The ClinicalTrials.gov registry entry for NCT04339036 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (61% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine Oral Product is the first listed.
NCT04339036 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04339036 about?
NCT04339036 is a clinical study titled "CapTemY90 for Grade 2/3 NET Liver Metastases". This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation fr...
What is the current status of trial NCT04339036?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-10-07. Estimated completion is 2026-05-01.
What conditions does trial NCT04339036 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 2.
What interventions are being tested in trial NCT04339036?
The interventions under investigation include: Capecitabine Oral Product (DRUG), Temozolomide Oral Product (DRUG), transarterial radioembolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04339036?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04339036 being conducted?
This trial has 4 study locations across California, Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.